Inactivating mutations of the Ten-Eleven translocation (TET)2 gene were first identified in myeloid malignancies and more recently in peripheral T-cell lymphomas (PTCL). We investigated the presence of TET2 coding sequence mutations and their clinical relevance in a large cohort of 190 PTCL patients. TET2 mutations were identified in 40/86 (47%) angioimmunoblastic T-cell lymphomas (AITL), 22/58 (38%) peripheral T-cell lymphomas, not otherwise specified (PTCL-NOS), but were absent in all other PTCL entities except 2/10 enteropathy-associated T-cell lymphoma.
Introduction
Inactivating mutations of the Ten-Eleven translocation (TET)2 gene were first identified in myeloid malignancies 1, 2 . TET2 encodes a 2 oxoglutarate/Fe2+ dependent oxygenase that catalyses the oxidation of 5-methylcytosine to 5-hydroxymethylcytosine [3] [4] [5] , and its inactivation in mouse results in expansion of the hematopoietic progenitor cells and in pleiotropic abnormalities affecting both myeloid and lymphoid lineages [6] [7] [8] . Recently, TET2 mutations have been reported in human lymphomas with a higher frequency in T-cell than in B-cell-derived neoplasms (12% versus 2%) 7, 9 . Among peripheral T-cell lymphomas (PTCL), the mutations identified were almost exclusively in angioimmunoblastic T-cell lymphoma (AITL) and PTCL, not otherwise specified (PTCL-NOS) subtypes, the two most common PTCL entities in western countries 10 . These mutations were demonstrated in tumor cells, with evidence that they may be acquired either in early CD34+ progenitors or at later steps of lymphoid development 7 .
Here, we extend the analysis of TET2 mutations to a larger independent series of PTCL samples, with an attempt to correlate the mutational status to pathological features and clinical outcome.
Materials and methods

Patients and tumour samples
A series of 190 PTCL patients with frozen lymphoma samples available at diagnosis were selected within the framework of a multicentric T-cell lymphoma consortium (Tenomic). The study was approved by the local ethic committee (CPP Ile de France IX= 08-009). Clinical data were retrospectively collected. All cases were reviewed and a consensus diagnosis was made at multihead microscope by 3 hematopathologists, according to the criteria of the 2008 WHO classification 11 .
Within PTCL-NOS, a group without typical morphology of AITL but expressing T FH markers (PD1, BCL6 and/or CXCL13) and/or having some other features reminiscent of AITL [i.e. presence of 2 of the following criteria: CD20-positive large B-cells, EBV-encoded small RNAs(EBER)-positive cells , CD21 and/or CD23 follicular dendritic cell expansion, CD10 expression] was designated "TFH-like" PTCL-NOS.
TET2 genotyping
DNA was extracted from several frozen tissue sections with morphological control using QIAamp DNA mini Kit (Quiagen, LesUlis, France) and an aliquot amplified by linear amplification. Analysis of the coding sequences of TET2 was performed by direct sequencing of the PCR fragments and candidate mutations were confirmed by sequencing an independent PCR product amplified from native genomic DNA, as previously described 7 . Frameshift, nonsense mutations, mutations in splice site, and missense mutations (only those affecting the evolutionary conserved regions of the protein) were considered. Single nucleotide polymorphisms (SNP) either previously published or recorded in the National Center for Biotechnology Information SNP database were excluded.
Statistical analysis
Continuous and dichotomic variables were compared with the Wilcoxon sum rank test or
Cochrane Armitage and Khi-2 or Fisher's exact tests. Overall survival (OS) and progressionfree survival (PFS) were estimated using the Kaplan-Meier method and compared with the log rank test. All tests were two-sided and P values <0.05 were considered significant.
Results and Discussion
TET2 mutations were found in 64/190 samples at diagnosis (34%). The frequency of TET2 mutations was extremely variable according to the diagnosis category. TET2 mutations were present in 40/86 (47%) AITL, in 22/58 (38%) PTCL-NOS and in 2/10 (20%) enteropathyassociated T-cell lymphoma. By contrast, no mutation was observed in any of the 18 anaplastic large cell lymphomas (12 ALK-positive, 6 ALK-negative), the 12 extranodal NK/T lymphomas, nasal-type and the 6 hepatosplenic T-cell lymphomas tested (Table 1) .
Interestingly, and in accordance with the previous report 7 the highest frequency of mutations was found in AITL, which is thought to derive from T FH cells normally present in germinal centers [12] [13] [14] . Within the large group of PTCL-NOS, it is also now recognized that a subset has "T FH -like" features in the form of a molecular profile bearing imprints of T FH cell signature, the expression of T FH -associated molecules [15] [16] [17] and/or overlapping pathological features 16 . Thus, we questioned whether TET2 mutations correlated with T FH -like features in PTCL-NOS. Among the 58 PTCL-NOS in our series, 24 were classified as "T FH -like" PTCL-NOS. TET2 mutations were present in 14/24 (58%) of the T FH -like PTCL subgroup compared to 8/34 (22%) in those lacking AITL features and T FH -markers. Therefore, TET2 mutations in PTCL appear to correlate with T FH derivation, i.e occur at higher frequency in AITL and T FHlike PTCL-NOS, than in non-T FH -like PTCL-NOS and other PTCL entities (49% vs 12,5%, p<0.0001).
Among the 64 PTCL patients with TET2 mutations, 37 had single mutations and 27 had 2 or more mutations. TET2 mutations were mainly insertions/deletions generating frameshifts and nonsense mutations, similar to those found in myeloid malignancies (Table S1 ). Eighteen of 19 missense mutations were predicted as probably damaging by the polyphen software (http://genetics.bwh.harvard.edu/pph2/) and one as possibly damaging. For three mutated patients with available biopsy at relapse, an identical pattern of TET2 mutations was found in paired samples ( Figure S1 ), suggesting that TET2 mutations are associated with the main driving clone.
When focusing on AITL and PTCL-NOS patients (n=144), 62 patients had TET2
mutations and 82 were TET2 wildtype. Clinical factors associated with TET2 mutated status (Table 2 and Figure S2 ) were advanced stage disease (p=0.02), increased number of involved extranodal sites (p=0.017), presence of B symptoms (p=0.02), thrombocytopenia (p=0.04), high International Prognosis Index (IPI) (p=0.028) and Prognosis Model for PTCL-NOS (PIT) 18 (p=0.025) scores, indicating that TET2 mutations are associated with adverse clinical parameters at presentation. Despite incomplete clinical data and heterogeneous therapies in this multicentric retrospective cohort, anthracyclin-based chemotherapy was the most common regimen in both mutated and non-mutated groups (73% and 70% respectively). In this retrospective study, TET2-mutated patients with AITL or PTCL-NOS appeared to have a shorter PFS (p=0.04) than TET2-wildtype patients, but no significant difference in OS was observed (p=0.1) ( Figure S2 ). The association between TET2 mutations, poor prognosis clinical parameters and outcome was even stronger when focusing on the group of patients with AITL and T FH -like PTCL-NOS. In this group, TET2 mutations were associated with a shorter PFS (p=0.022) and a trend to a shorter overall survival (p=0.058) (Table S2 and   Figure S3) We recently reported recurrent IDH2 mutations in AITL 19 . These mutations alter IDH enzymatic function and may result in the functional inactivation of TET protein activity 20 . In acute myeloid leukemia, IDH and TET2 mutations are reported mutually exclusive 20 . Of the 31 AITL samples from the current study also analysed for IDH2 mutations 19 , 6 cases disclosed both IDH2 and TET2 mutations, 2 cases were IDH2 mutated/TET2 wildtype and 10 cases were TET2 mutated/IDH2 wildtype, indicating that both mutations can accumulate in AITL. Ultimately, both IDH2 and TET2 mutations, recurrent in AITL and in T FH -derived PTCL may deregulate the control of chromatin structure. This situation may be reminiscent of that observed in B-cell lymphomas, in which mutations of several genes involving epigenetic changes and chromatin remodelling, such as CREEBP, EP300 21 , EZH2 22 , MLL2 or MEF2B 23 have recently been described.
In addition to similarities in their ontogeny, AITL and a subset of T FH -like PTCL share common oncogenic alterations including TET2 abnormalities, further supporting their close relationship. The strong association between TET2 mutations, AITL and T FH -like PTCL may provide molecular rationale to merge together AITL and PTCL-NOS expressing T FH markers as previously suggested 15, 16 and to refine the spectrum of AITL. Overall, the identification of frequent TET2 mutations in AITL and other T FH -related PTCL extends the importance of epigenetic alterations in lymphomagenesis. These results suggest that, in these diseases in which conventional chemotherapies are ineffective 24 in most patients, the use of new agents, such as demethylating agents should be considered.
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